This was also supported by the results of RASSF1A average methylation in Her2/Neu overexpressed tumors (38% ± 17%) and the RASSF1A average methylation seen in triple-negative breast cancer (TNBC) (10% ± 9.5%; please see Figure 3). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.